Somewhat Positive Press Coverage Somewhat Unlikely to Impact Omeros Corporation (NASDAQ:OMER) Share Price
News stories about Omeros Corporation (NASDAQ:OMER) have trended somewhat positive on Sunday, according to Accern Sentiment. The research group rates the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Omeros Corporation earned a media sentiment score of 0.22 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 46.8069278637123 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
These are some of the news headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Omeros Hoists Sales (seekingalpha.com)
- Omeros to Present at the 2017 Wedbush PacGrow Healthcare Conference (finance.yahoo.com)
- Today’s Research Reports on Trending Tickers: Omeros Corporation and Zynerba Pharmaceuticals (finance.yahoo.com)
- Jane Fonda Have Love In The Our Souls At Night Trailer (famososartistas.com)
- Omeros Corporation : Investor Network: Omeros Corporation to Host Earnings Call (4-traders.com)
OMER has been the topic of several research analyst reports. Cantor Fitzgerald lowered Omeros Corporation from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $21.00 to $15.00 in a research note on Thursday, May 11th. Maxim Group set a $23.00 price objective on Omeros Corporation and gave the company a “buy” rating in a research note on Thursday, May 11th. Wedbush reaffirmed an “outperform” rating and issued a $47.00 price objective on shares of Omeros Corporation in a research note on Wednesday, May 10th. ValuEngine upgraded Omeros Corporation from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Finally, Cowen and Company reiterated an “outperform” rating on shares of Omeros Corporation in a report on Saturday, June 3rd. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $32.80.
Shares of Omeros Corporation (NASDAQ:OMER) opened at 23.45 on Friday. The company’s 50 day moving average price is $21.51 and its 200 day moving average price is $16.16. Omeros Corporation has a one year low of $7.20 and a one year high of $27.09. The stock’s market capitalization is $1.05 billion.
Omeros Corporation (NASDAQ:OMER) last released its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.12. The company had revenue of $17.15 million for the quarter, compared to the consensus estimate of $14.63 million. The business’s revenue was up 71.5% compared to the same quarter last year. During the same quarter last year, the company posted ($0.32) EPS. On average, equities analysts expect that Omeros Corporation will post ($1.26) earnings per share for the current year.
In other news, VP Michael A. Jacobsen sold 12,000 shares of the company’s stock in a transaction dated Friday, June 16th. The stock was sold at an average price of $24.95, for a total transaction of $299,400.00. Following the completion of the sale, the vice president now owns 19,500 shares in the company, valued at approximately $486,525. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, VP Michael A. Jacobsen sold 24,000 shares of the company’s stock in a transaction dated Thursday, June 15th. The stock was sold at an average price of $21.20, for a total value of $508,800.00. Following the sale, the vice president now owns 2,650 shares of the company’s stock, valued at approximately $56,180. The disclosure for this sale can be found here. Corporate insiders own 13.60% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This article was first reported by Daily Political and is the property of of Daily Political. If you are reading this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this article can be read at https://www.dailypolitical.com/2017/08/13/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-omeros-corporation-nasdaqomer-share-price.html.
About Omeros Corporation
Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.
Receive News & Ratings for Omeros Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Corporation and related companies with MarketBeat.com's FREE daily email newsletter.